Content

Sl. NO	DESCRIPTION	PAGE NO
	Chapter 1. Introduction	
1.	Introduction	1
1.1	Natural Products: A continuing source for drug discovery	1-2
1.2.	Herbal Medicine derived from Natural products	2-3
1.3.	Medicinal Plants: Future Source of New Drug	3-5
1.4.	Ethnomedicinal Plants from Darjeeling Himalayan Region	6-8
1.5.	Drug Development from medicinal Plants: Phytochemical and Phyto Therapeutic Approaches	8-9
1.6	Antioxidant, antidiabetic, anti-inflammatory details	9
1.7.	Research work	10
1.8.	Aim and objectives	10
1.9.	References	10-14
	Chapter 2. Literature review on Himalayan region and Selected plants	
2.1.	Introduction	15
2.1.1	Socioeconomic Status of People	15-16
2.1.2	Ethnomedicinal plant from Darjeeling hills	16-17
2.2.	Literature Review on *Asparagus racemosus* Willd	17-25
2.2.1.	Introduction of Investigated Plant	17
2.2.2.	Ecological niche of *A. racemosus* Willd	17
2.2.3.	The taxonomic details of the plant *A. racemosus*	18
2.2.4.	Common Names	18
2.2.5.	Vernacular Names	18-19
2.2.6.	Geographical distribution	19
2.2.7	Morphology of *A. racemosus* Willd	19
2.2.8	Description	19-20
2.2.9.	Phytoconstituents of *A. racemosus* Willd	20-23
2.2.10.	Ethnomedicinal use	23-24
2.2.11.	Scientific exploration	24-25
2.3.	Literature Review on *Duabanga grandiflora*	25-27
2.3.1.	Introduction of Investigated Plant	25
2.3.2.	The taxonomic details of *Duabanga grandiflora*	25
2.3.3.	Common names	26
2.3.4.	Vernacular names	26
2.3.5.	Geographical distribution	26
2.3.6.	Morphological description of *Duabanga grandiflora*	26

Sl. NO	DESCRIPTION	PAGE NO
2.3.7.	Phytoconstituents and Pharmacological activity	25-26
2.3.8.	Conclusion	27
2.3.9.	References	27-30
	Chapter 3. Pharmacognostic Evaluation of *Asparagus racemosus Willd and Duabanga grandiflora*	
3.1.	Introduction	31-32
3.2.	Materials and Methods	32-37
3.2.1.	Collection and authentication of plant material	32-33
3.2.2.	Pharmacognostic Studies	33-37
3.2.2.1.	Organoleptic and Macroscopic studies of *A.racemosus* and *D.grandiflora*	33
3.2.2.2.	Microscopic studies of *A.racemosus* and *D.grandiflora*	33-35
3.2.2.2.1	Preparation of sample for transverse sectioning	33
3.2.2.2.2.	Staining	33
3.2.2.2.3.	Photomicrographs	34
3.2.2.2.4.	Powder Microscopy	34
3.2.2.3.	Physicochemical Analysis	35
3.2.2.3.1.	Extractive values	35-36
3.2.2.3.2.	Ash values and loss on drying	36
3.2.2.4.	Behavioral pattern/ Fluorescence analysis of the plant powder	37
3.3	Result	37-50
3.3.1.	Pharmacognostical Study of *A. racemosus* willd	37
3.3.1.1.	Macroscopic study and Organoleptic properties	37-38
3.3.1.2.	Microscopic study	38-41
3.3.1.2.1.	Staining	40
3.3.1.2.2.	Powder Microscopy	40-41
3.3.1.3.	Physicochemical content	41-43
3.3.1.3.1.	Extractive Value	41
3.3.1.3.2.	Ash value	42
3.3.1.4.	Fluorescence analysis	42-43
3.3.2.	Pharmacognostical Study of *D. grandiflora*	43-50
3.3.2.1.	Organoleptic/ Macroscopic study	43
3.3.2.2.	Microscopic study	44-45
3.3.2.2.1.	Powder Microscopy	45-46
3.3.2.3.	Physicochemical content	47-48
3.3.2.3.1.	Extractive values	47
3.3.2.3.2.	Ash values and loss on drying	47
3.3.2.4.	Fluorescence analysis for Leave Parts of *D. grandiflora*	48-49

Sl. NO	DESCRIPTION	PAGE NO
3.3.2.4.1.	Fluorescence analysis for Flowering section of *D. grandiflora*	49
3.3.	Results and Discussion	49-50
3.4.	Conclusion	50
3.5.	References	50-52
	Chapter 4. Phytochemical investigation of *Asparagus racemosus Willd and Duabanga grandiflora*	
4.1.	Introduction	53-54
4.2.	Material and methods	54-57
4.2.1.	Plant material	54
4.2.2.	Extraction procedure	54-55
4.2.3.	Phytochemical analysis	55
4.2.3.1.	Preliminary phytochemical test	55-57
4.3.	Results & Discussion	58-60
4.3.1.	Phytochemical Analysis of *A.racemosus*	58
4.3.2.	Phytochemical Analysis of *D. grandiflora's* Leaves and flowers	59
4.4.	Conclusion	60
4.5.	References	60-61
	Chapter 5. Phytochemical profiling through analytical techniques	
5.1.	Introduction	62
5.1.1.	Detailed about phytochemical markers	62-63
5.1.2.	Role of HPTLC to identify chemical marker	64-65
5.1.3.	Importance of GCMS and LCMS	65-67
5.2.	Materials and methodology	67-73
5.2.1.	Apparatus and chemicals	67
5.2.2.	Preparation of samples and standards	67-68
5.2.3.	HPTLC analysis	68
5.2.4.	Microchemical derivatization	68-69
5.2.5.	Biochemical derivatization	69-70
5.2.6.	ATR–FTIR spectroscopy	70
5.2.6.1.	ATR-FTIR and NMR analysis for DPPH activity and α-amylase activity	71
5.2.7.	Method validation and quantitative estimation of standards	71-72
5.2.8.	Statistical analysis	72
5.2.9.	GC-MS analysis of *A. racemosus* methanolic extract from aerial parts and *D. grandiflora's* methanolic extract of leaves	72
5.2.10.	LC-MS analysis for Phytochemical screening of *A. racemosus* methanolic extract from aerial parts and *D. grandiflora's*	72-73

Sl. NO	DESCRIPTION	PAGE NO
	methanolic extract of leaves	
5.3.	Result and Discussions of HPTLC for *A.racemosus* aerial part	73-87
5.3.1.	Microchemical derivatization for *A.racemosus* aerial part	73-74
5.3.2.	FTIR analysis HPTLC for *A.racemosus* aerial part	74-75
5.3.3.	HPTLC method validation and quantitative estimation of *A.racemosus* aerial extract	76-79
5.3.4.	HPTLC method validation for α-amylase and quantitative estimation of *A.racemosus* aerial extract	80-81
5.3.5.	Quantification of Antioxidant activity and α-amylase inhibition	81-85
5.4.	HPTLC study of microbial derivitization for *D.grandiflora*	85-86
5.5.	HPTLC study of *D.grandiflora* biochemical derivitization	86-87
5.6.	GCMS study for *A.racemosus* methanolic extract	88-94
5.7.	GCMS study for methanolic extract of *D. grandiflora* Leaves and flowering part	88-104
5.8.	LCMS study of methanolic extract from *A.racemosus* aerial part and *D.grandiflora* leaves part	104-109
5.9.	Conclusion	109
5.10.	References	110-125
	Chapter 6. *In vitro* anti-oxidant activity	
6.1.	Introduction	126-127
6.2.	Material and method	127-130
6.2.1.	Plant material	127
6.2.2.	Preparation of different extract	127-128
6.2.3.	Chemicals	128
6.2.4.	Determination of total phenolic content (TPC)	128
6.2.5.	Determination of Total flavonoids content (TFC)	128-129
6.2.6.	*In vitro* Antioxidant assays	129-130
6.2.6.1.	Determination of DPPH free radical scavenging activity	129
6.2.6.2.	Determination of reducing power	129
6.2.6.3.	Metal chelating Assay	130
6.3.	Result & Discussion	130-139
6.3.1.	Determination of total phenolic compounds (TPC)	130
6.3.1.1	Determination of TPC of *A. racemosus willd*	130-131
6.3.1.2.	Determination of TPC of *D. grandiflora*	131
6.3.2.	Total flavonoids determination (TFC)	132
6.3.2.1.	Determination of TFC of *A.racemosus willd*	132
6.3.2.2.	Determination of TFC of *D. grandiflora*	132-133

Sl. NO	DESCRIPTION	PAGE NO
6.3.3.	DPPH free-radical scavenging activity	133
6.3.3.1.	DPPH antioxidant activity of *A.racemosus*	133-134
6.3.3.2.	DPPH free-radical scavenging activity of *D. grandiflora*	134-135
6.3.4.	Determination of reducing power	135
6.3.4.1.	Determination of reducing power assay of *A.racemosus*	136
6.3.4.2.	Determination of reducing power assay of *D. grandiflora*	136-137
6.3.5.	Metal chelating Assay	137
6.3.5.1.	Determination of metal chelation of *A.racemosus willd*	138
6.3.5.2.	Determination of metal chelation of *D. grandiflora*	138-139
6.4.	Conclusion	139
6.5.	References	140-141
	Chapter 7. Study of *in vitro* anti-diabetic activity	
7.1.	Introduction	142-143
7.1.1.	Role of α-amylase enzyme in diabetes	143-144
7.1.2.	Role of α-glucosidase enzyme in diabetes	144-145
7.2.	Methodology	145-146
7.2.1.	α-Amylase Inhibition Assay	145
7.2.2.	α-Glucosidase inhibition assay	145-146
7.3.	Results & Discussion	146-149
7.3.1.	α-Amylase inhibitory activity of *A.racemosus*	146
7.3.2.	α-Amylase inhibitory activity of *D. grandiflora*	147
7.3.3.	α-Glucosidase inhibitory Activity of *A.racemosus*	147-148
7.3.4.	α- Glucosidase inhibitory activity of *D. grandiflora*	148-149
7.4.	Conclusion	149
7.5.	References	149-152
	Chapter 8. *In vitro* anti-inflammatory study	
8.1.	Introduction	153-154
8.2.	Materials and methods	154-156
8.2.1.	Plant materials	154-155
8.2.2.	Extraction of *A. racemosus willd and D. grandiflora*	155
8.2.3.	Chemicals	155
8.3.	*In vitro* Anti-inflammatory assays	155
8.3.1.	Protein denaturation assay	155-156
8.4.	Results and Discussion	156-158
8.4.1.	Protein denaturation assay of *A. racemosus*	156-157
8.4.2.	Protein denaturation assay of *D. grandiflora*	157-158
8.5	Conclusion	158
8.6	References	159-160

Sl. NO	DESCRIPTION	PAGE NO
	Chapter 9. *In vitro* anti-microbial activity study	
9.1.	Introduction	161
9.1.1.	Medicinal plants in Antimicrobial Study	161-163
9.2.	Materials and Methods	163-165
9.2.1.	Plant material	163
9.2.2.	Extraction of *A. racemosus and D. grandiflora*	163-164
9.2.3.	Chemicals	164
9.2.4.	Preparation of sample	164
9.2.5.	Selection of microorganisms	164
9.2.6.	Antimicrobial activity	164-165
9.2.7.	Preliminary screening for antimicrobial activity	165
9.2.8.	Minimum Inhibitory concentration (MIC) of *A. racemosus and D. grandiflora's* methanolic extract	165
9.3.	Result and Discussion	166-169
9.4.	Conclusion	169
9.5.	References	169-172
	Chapter 10. *In vitro* cytotoxic activity study	
10.1.	Introduction	173-174
10.1.1.	Medicinal plants with cytotoxic activity in cancer therapy	174-176
10.2.	Materials and Methods	176-177
10.2.1.	Plant material	176
10.2.2.	Extraction of *A. racemosus and D. grandiflora*	176
10.2.3.	Chemicals	176-177
10.2.4.	*In vitro* Cytotoxicity assays	177
10.2.4.1.	MTT assay	177
10.3.	Results and Discussion	177-179
10.3.1.	MTT assay of *A. racemosus* aerial part	177-178
10.3.2.	MTT assay of of *D. grandiflora*	179
10.4.	Conclusion	179-180
10.5.	References	180-181
	Chapter 11. *In vivo* Antidiabetic activity of *Asparagus racemosus willd and Duabnaga grandiflora*	
11.1.	Introduction	182
11.1.1.	Pathophysiology	182-185
11.1.2.	Model of Type 2 diabetes	185
11.1.3.	Medicinal Plants in Treatment of Type 2 Diabetes	186-187
11.1.4.	Mechanisms behind the anti-diabetic activity of Medicinal Plants:	187-188
11.2.	Materials and Methods	188-192

Sl. NO	DESCRIPTION	PAGE NO
11.2.1.	Plant material	188
11.2.2.	Preparation of methanolic extracts from the Aerial part of *Asparagus racemosus* and Leaves of *Duabanga grandiflora*	189
11.2.3.	Chemicals	189
11.3.	*In vivo* antidiabetic assay of *Asparagus racemosus and Duabanga grandiflora*	189
11.3.1.	Animals for *in vivo* study	189
11.3.2.	Acute toxicity studies of both *A. racemosus* and Leaves of *D.grandiflora* extracts in rat	190
11.3.3.	Oral Glucose tolerance test (OGTT)in in healthy rats	190
11.3.4.	Type 2 diabetes inductions	190
11.3.5.	Experimental design	191
11.3.6.	Assessment of serum parameters	191
11.3.7.	Assessment of Oxidative stress markers in liver tissues	192
11.3.7.1.	Preparation of liver homogenate	192
11.3.7.2.	Determination of Lipid peroxidation	192
11.3.7.3.	Determination of Catalase	192
11.3.7.4.	Determination of Reduced glutathione	192
11.3.8.	Histopathological studies	192
11.4.	Results and discussion	193-203
11.4.1.	Acute toxicity study in rat	193
11.4.2.	Oral Glucose tolerance test (OGTT)	193-194
11.4.3.	Effect of methanolic extracts of *Asparagus racemosus and Duabanga grandiflora* on FBS and body weight in STZ-Nicotinamide-induced diabetic rat	194-196
11.4.4.	Evaluation of Biochemical parameters of blood in diabetic rats treated with methanolic extracts of *Asparagus racemosus and Duabanga grandiflora*	196-197
11.4.5.	Effect of methanolic extracts of *Asparagus racemosus willd and Duabanga grandiflora* on oxidative stress in the liver of diabetic rats	198-199
11.4.6.	Histopathology of liver, kidney, and heart of rats	199-201
11.5.	Discussion	201-203
11.6.	Conclusion	204
11.7.	References	204-210
	Chapter 12. Study of Anti-Inflammatory activity of Methanolic extracts from *Asparagus racemosus* Willd's aerial part and *Duabanga grandiflora's* leaves	

Sl. NO	DESCRIPTION	PAGE NO
12.1.	Introduction	211
12.1.1.	Cellular homeostasis and inflammatory responses	211-212
12.1.2.	Mechanism of Inflammatory response	212-214
12.1.3.	Medicinal plants in the treatment of Inflammation	214-215
12.1.4.	Mechanisms of Plants in the treatment of Inflammation	215-217
12.2.	Materials and methods	217-219
12.2.1.	Plant material	217
12.2.2.	Preparation of methanolic extracts from the Aerial part of *A. racemosus* and Leaves of *D. grandiflora*	218
12.2.3.	Chemicals	218
12.2.4.	Animals required	218
12.2.5.	Doses	218
12.2.6.	Anti-inflammatory activity *in vivo* models	219
12.2.6.1.	Carrageenan-induced paw edema in rats (acute models)	219
12.2.6.2.	Statistical analysis	219
12.3.	Results	219-220
12.4.	Discussion	220
12.5.	References	221-224
	Chapter 13. Green Synthesis of Silver Nano particles from *Asparagus racemosus* Willd	
13.1.	Introduction	225-226
13.1.2.	Materials for Nanoparticles Synthesis	226
13.1.3.	Synthesis methods for NPs	226-227
13.1.4.	Different approaches of producing NPs via green synthesis	227-228
13.1.5.	Metal used to form Nanoparticles via green synthesis	229-230
13.2.	Materials and Methodology	230-236
13.2.1.	Chemicals and materials	230
13.2.2.	Preparation of the *A. racemosus* willd aerial extract	230-231
13.2.3.	Green synthesis of silver nanoparticles	231
13.2.4.	Characterization of Synthesized nanoparticle UV-VIS Spectrophotometry analysis of AgNPs-AR	231-232
13.2.5.	Fourier-transformed infrared (FTIR) spectroscopy of AgNPs-AR	232
13.2.6.	XRD analysis of AgNPs-AR	232
13.2.7.	Particle size and Zeta potential of AgNPs-AR	232
13.2.8.	Scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDX) of AgNPs-AR	232
13.2.9.	Transmission electron microscopy (TEM) of AgNPs-AR	233
13.2.10.	Pharmacological activities of AgNPs-AR	233-236

Sl. NO	DESCRIPTION	PAGE NO
13.2.10.1.	Free radical scavenging activity (DPPH)	233
13.2.10.2	Ferric-reducing power assay	233-234
13.2.10.3	α-Amylase inhibition assay	234
13.2.10.4.	*In vitro* cell viability assay [MTT assay]	234-235
13.2.10.5	Antimicrobial assay of AgNPs-AR	235
13.2.10.6	Determination of minimum inhibitory concentration (MICs) and minimum bactericidal concentration (MBC) of AgNPs-AR:	235-236
13.2.11.	Statistical analysis	236
13.3.	Result and discussion	236-246
13.3.1.	UV-Visible spectral analysis	236-237
13.3.2.	Fourier transform infrared (FTIR) spectroscopy	237-238
13.3.3.	XRD Analysis	239-239
13.3.4.	Particle size and Zeta potential of AgNPs-AR	239-240
13.3.5.	SEM and EDX analysis	240-241
13.3.6.	TEM	241
13.3.7.	Biological activity	242-246
13.3.7.1.	Free radical scavenging activity (DPPH) of AgNPs-AR	242
13.3.7.2.	Reducing Power Assay of AgNPs-AR	242-243
13.3.7.3.	α-amylase inhibition activity of AgNPs-AR	243-244
13.3.7.4.	Cytotoxicity potential of AgNPs-AR	244-245
13.3.7.5.	Anti-microbial activity of AgNPs-AR	244-245
13.4.	Conclusion	247
13.5.	References	247-253
	Chapter 14. Formulation of silver nanoparticles using *Duabanga grandiflora* leaf extract and evaluation of their versatile therapeutic applications	
14.1.	Introduction	254-256
14.2.	Materials and Methodology	256-260
14.2.1.	Chemicals	256
14.2.2.	Preparation of the extract *D. grandiflora* leaves	256
14.2.3.	Green synthesis of of AgNPs from *D. grandiflora's* Leaves extract	256
14.2.4.	Characterization of *D. grandiflora*-mediated silver nanoparticles	256-258
14.2.4.1.	UV analysis of *D. grandiflora*-mediated silver nanoparticles	257
14.2.4.2.	FTIR analysis of *D. grandiflora*-mediated silver nanoparticles	257
14.2.4.3.	XRD analysis of *D. grandiflora*-mediated silver nanoparticles	257
14.2.4.4.	Particle size and Zeta potential of *D. grandiflora*-mediated silver nanoparticles	257
14.2.4.5.	Scanning electron microscopy (SEM) and energy-dispersive X-ray	258

Sl. NO	DESCRIPTION	PAGE NO
	spectroscopy (EDX) of *D. grandiflora*-mediated silver nanoparticles	
14.2.4.6.	Transmission electron microscopy (TEM) of D. grandiflora-mediated silver nanoparticles	258
14.2.5.	Biological activities of *D. grandiflora*-mediated silver nanoparticles	258-260
14.2.5.1.	Anti-oxidant activity (DPPH) *D. grandiflora*-mediated silver nanoparticles	258
14.2.5.2.	Anti-diabetic activity of *D. grandiflora*-mediated silver nanoparticles	258-259
14.2.5.3.	Cytotoxicity assay [MTT assay] *D. grandiflora*-mediated silver nanoparticles	259
14.2.5.4.	Antibacterial activity of *D. grandiflora*-mediated silver nanoparticles	259-260
14.2.5.5.	MIC of *D. grandiflora*-mediated silver nanoparticles	260
14.2.6.	Statistical analysis	260
14.3.	Result and discussion	260-269
14.3.1.	UV-Visible spectral analysis	260-261
14.3.2.	Fourier transform infrared (FTIR) spectroscopy	261-262
14.3.3.	XRD Analysis	263
14.3.4.	Particle size and Zeta potential	263-264
14.3.5.	SEM and EDX analysis	264
14.3.6.	TEM	265
14.3.7.	Anti-oxidant activity	265-266
14.3.8.	Anti-diabetic activity	266
14.3.9.	Cytotoxicity activity	267
14.3.10.	Anti-microbial activity	267-269
14.4	Conclusion	269
14.5	References	270-273
	Chapter 15. Conclusion	274